antisense

positive negative up down good bad mixed

Biotech

Biogen advances Alzheimer’s tau program despite midphase miss

While the study failed to yield the hoped-for dose-response data, reductions in tau and cognitive benefits led Biogen to commit to a pivotal trial.

Nick Paul Taylor May 14, 2026 8:35am

Link

Biogen links up with Alloy platform to boost ASO drug development

Apr 7, 2026 6:00am

base camp tent mountain summit

GSK pays $17.5M for CAMP4 regulatory RNA deal

Dec 18, 2025 7:00am

sarepta building

Fierce Pharma

Sarepta, despite key trial flop, will seek full nod for DMD meds

Nov 4, 2025 7:56am

Crossing crosswalk walking road

Ionis rare disease candidate ekes out phase 3 win

Sep 22, 2025 10:46am

An artists 3D rendering of cancerous blood cells among healthy red blood cells The cells fill the image and are of various

Ono pays $280M upfront for Ionis' phase 2 blood cancer med

Mar 12, 2025 6:30am